Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
Denali Gains 26.6% in a Year: How Should You Play the Stock?
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
Denali Therapeutics’ (DNLI) Outperform Rating Reiterated at William Blair
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...
ETF Daily News5d
Denali Therapeutics Inc. (NASDAQ:DNLI) Sees Significant Increase in Short Interest
Denali Therapeutics stock opened at $21.93 on Monday. The firm’s 50 day moving average price is $23.13 and its 200-day moving average price is $24.79. Denali Therapeutics has a 1 year low of $14 ...
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.
Nasdaq3d
Denali Gains 26.6% in a Year: How Should You Play the Stock?
Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...
Insider Monkey7d
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential
In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...